RB

Rebus Holdings IncOOTC RBSH Stock Report

Last reporting period 30 Sep, 2022

Updated 13 Nov, 2024

Last price

Market cap $B

0.003

Micro

Exchange

OOTC - OTC

RBSH Stock Analysis

RB

Uncovered

Rebus Holdings Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

0.003

Dividend yield

Shares outstanding

32.133 B

Website

Rebus Holdings, Inc. is a pharmaceutical company engaged in the research and development of novel therapeutics for the treatment of cancer. The company is headquartered in Westlake Village, California. The company went IPO on 2009-11-02. The firm utilizes its proprietary delivery technology to enhance immuno-modulation for developed therapeutic outcomes. Its immune-oncology lead asset, RT-AR001, an adenosine A2A receptor antagonist, is differentiated by its intratumoral delivery of nano- or microparticle formulations that allows for better tumor infiltration. Its patented portfolio of adenosine receptor antagonists provides treatment based on the specific adenosine targets found in each type of cancer. The adenosine receptor modulators include A 2B antagonists, dual A 2A /A 2B antagonists, and A 2A antagonists that have broad development applicability including indications within immuno-oncology and inflammation.

View Section: Eyestock Rating